These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 1396201)

  • 1. Acetylation status using hydralazine in African hypertensives at Kenyatta National Hospital.
    Rashid JR; Kofi-Tsepko ; Juma FD
    East Afr Med J; 1992 Jul; 69(7):406-8. PubMed ID: 1396201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Different phenotypes of the NAT2 gene influences hydralazine antihypertensive response in patients with resistant hypertension.
    Spinasse LB; Santos AR; Suffys PN; Muxfeldt ES; Salles GF
    Pharmacogenomics; 2014 Feb; 15(2):169-78. PubMed ID: 24444407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The influence of the acetylator phenotype for the clinical use of dihydralazine.
    Siegmund W; Franke G; Biebler KE; Donner I; Kallwellis R; Kairies M; Scherber A; Hüller H
    Int J Clin Pharmacol Ther Toxicol; 1985 Apr; 23 Suppl 1():S74-8. PubMed ID: 3842694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hydralazine in arterial hypertension. Randomized double-blind comparison of conventional/Slow-Release formulation and of b.i.d./q.i.d. dosage regimens.
    Wulff K; Lenz K; Krogsgaard AR; Holst B
    Acta Med Scand; 1980; 208(1-2):49-54. PubMed ID: 7435247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Should the acetylator phenotype be determined when prescribing hydralazine for hypertension?
    Ramsay LE; Silas JH; Ollerenshaw JD; Tucker GT; Phillips FC; Freestone S
    Eur J Clin Pharmacol; 1984; 26(1):39-42. PubMed ID: 6714290
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Metabolism of hydralazine in man. Part II: Investigation of features relevant to drug safety.
    Dubois JP; Schmid K; Riess W; Hanson A; Henningsen NC; Andersson OK
    Arzneimittelforschung; 1987 Feb; 37(2):189-93. PubMed ID: 3580022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Dihydralazine therapy and acetylator phenotype.
    Iisalo E; Laine T; Lehtonen A; Sellman R
    Int J Clin Pharmacol Biopharm; 1979 Mar; 17(3):119-24. PubMed ID: 429082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genetically determined variability in acetylation and oxidation. Therapeutic implications.
    Clark DW
    Drugs; 1985 Apr; 29(4):342-75. PubMed ID: 2859977
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of dose on acetylator phenotype distribution of hydralazine.
    Timbrell JA; Harland SJ; Facchini V
    Clin Pharmacol Ther; 1981 Mar; 29(3):337-43. PubMed ID: 7471604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Propranolol-hydralazine combination in essential hypertension.
    Stevens JD; Binstok G; Mullane JF; Woods JW; Pittman AW; del Greco F; Huang C; Morledge JH
    Clin Ther; 1983; 5(5):525-39. PubMed ID: 6352036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Acetylator phenotyping in patients with malignant lymphomas, using caffeine as the metabolic probe.
    William BM; Abdel-tawab AM; Hassan EA; Mohamed OF
    Pol J Pharmacol; 2004; 56(4):445-9. PubMed ID: 15520499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Comparative analysis of N-acetylation polymorphism in humans as determined by phenotyping and genotyping].
    Goldenkova-Pavlova IV; Bruskin SA; Abdeev RM; Markarova EV; Bigvava SG; Radkevich LA; Kozhekbaeva ZhM; Glotov AS; Gra OA; Zasedatelev AS; Nasedkina TV; Kurdanov KhA; Piruzian ES
    Genetika; 2006 Aug; 42(8):1143-50. PubMed ID: 17025166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of hydralazine, an antihypertensive and DNA-demethylating agent, using controlled-release formulations designed for use in dosing schedules based on the acetylator phenotype.
    Gonzalez-Fierro A; Vasquez-Bahena D; Taja-Chayeb L; Vidal S; Trejo-Becerril C; Pérez-Cardenas E; de la Cruz-Hernández E; Chávez-Blanco A; Gutiérrez O; Rodriguez D; Fernandez Z; Duenas-González A
    Int J Clin Pharmacol Ther; 2011 Aug; 49(8):519-24. PubMed ID: 21781652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Genetic selection of volunteers and concomitant dose adjustment leads to comparable hydralazine/valproate exposure.
    Garcés-Eisele SJ; Cedillo-Carvallo B; Reyes-Núñez V; Estrada-Marín L; Vázquez-Pérez R; Juárez-Calderón M; Guzmán-García MO; Dueñas-González A; Ruiz-Argüelles A
    J Clin Pharm Ther; 2014 Aug; 39(4):368-75. PubMed ID: 24702251
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of microalbuminuria with slow acetylator phenotype in type 1 diabetes mellitus.
    Madácsy L; Szórády I; Sánta A; Barkai L; Vámosi I
    Child Nephrol Urol; 1992; 12(4):192-6. PubMed ID: 1473091
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Caffeine acetylator phenotyping during maturation in infants.
    Pariente-Khayat A; Pons G; Rey E; Richard MO; D'Athis P; Moran C; Badoual J; Olive G
    Pediatr Res; 1991 May; 29(5):492-5. PubMed ID: 1896253
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Isoniazid acetylation phenotyping in Saudi Arabs.
    Matar KM; Mayet AY; Ayoola EA; Bawazir SA; Al-Faleh FZ; Al-Wazzan A
    J Clin Pharm Ther; 2004 Oct; 29(5):443-7. PubMed ID: 15482388
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Isoniazid acetylation metabolic ratio during maturation in children.
    Pariente-Khayat A; Rey E; Gendrel D; Vauzelle-Kervroëdan F; Crémier O; d'Athis P; Badoual J; Olive G; Pons G
    Clin Pharmacol Ther; 1997 Oct; 62(4):377-83. PubMed ID: 9357388
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Acetylator genotype-dependent expression of arylamine N-acetyltransferase in human colon cytosol from non-cancer and colorectal cancer patients.
    Kirlin WG; Ogolla F; Andrews AF; Trinidad A; Ferguson RJ; Yerokun T; Mpezo M; Hein DW
    Cancer Res; 1991 Jan; 51(2):549-55. PubMed ID: 1985773
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Acetylator phenotype and the antihypertensive response to hydralazine.
    Jounela AJ; Pasanen M; Mattila MJ
    Acta Med Scand; 1975 Apr; 197(4):303-6. PubMed ID: 1136859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.